

Special Issue

Targeted and Stimulus-Responsive Nanomedicines for the Treatment of Central Nervous System (CNS) Disorders

Message from the Guest Editors

Despite tremendous efforts to create innovative treatments, CNS diseases are still among the diseases with the poorest outcomes for those affected. New strategies have to be designed to target and tackle the specificities of the BBB and the pathological conditions of CNS disorders. For instance, what are the specific translocation pathways used by nanocarriers to cross the BBB? What is the fate of nanocarriers in BBB endothelial cells according to their materials and/or targeting strategy? How can we improve both BBB translocation and brain cellular targeting? How can we exploit pathological microenvironment to improve specific drug or gene targeting? To answer those questions, we welcome contributions regarding:

- Methodologies to synthesize and characterize nanomedicines, lipid-, polymer- or hybrid-based nanocarriers for therapeutic, diagnostic or theranostic purposes;
- In vitro and in vivo proof-of-concepts for detecting or targeting brain disorders, i.e., using ligands, aptamers, peptides or stimuli-responsive strategies;
- Reports of novel receptors and pathways specifically involved in nanocarrier translocation to the CNS.

Guest Editors

Prof. Dr. Valérie Gaëlle Roullin
University of Montreal, Montreal, QC, Canada

Prof. Jeanne Leblond Chain
ARNA Laboratory, INSERM U1212, CNRS UMR 5320, University of Bordeaux, Faculty of Pharmacy, F-33016 Bordeaux, France

Deadline for manuscript submissions

closed (31 October 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/52945

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)